{ "schemaVersion": 2, "eyebrow": "Dermatology", "title": "Acanthosis Nigricans", "summary": "Acanthosis nigricans should prompt etiologic triage rather than cosmetic treatment alone: most cases reflect obesity-associated insulin resistance, but abrupt generalized, mucosal, or nonobese presentations require evaluation for medication, endocrine, autoimmune, and malignant drivers.", "seoDescription": "Clinical evaluation of acanthosis nigricans: distinguish insulin resistance from drug, endocrine, autoimmune, and malignancy-associated disease.", "clinicalQuestion": "How should clinicians evaluate acanthosis nigricans for metabolic disease, rare insulin-resistance syndromes, and internal malignancy?", "specialty": "Dermatology", "audience": "U.S. physicians and medical trainees", "tags": [ "acanthosis nigricans", "insulin resistance", "obesity", "type 2 diabetes", "polycystic ovary syndrome", "malignant acanthosis nigricans", "type B insulin resistance" ], "keyTakeaways": [ "In an overweight patient with symmetric intertriginous plaques, prioritize assessment for insulin resistance and its metabolic comorbidities; obesity is a stronger determinant of insulin resistance than acanthosis nigricans alone. [21][22]", "Document BMI, blood pressure, fasting glucose, hemoglobin A1c, fasting lipid profile, and alanine aminotransferase when acanthosis nigricans accompanies overweight or obesity. [19][24]", "Rapidly progressive, extensive, mucosal, or nonobesity-associated acanthosis nigricans warrants a directed search for malignancy and less common endocrine, medication-related, or autoimmune insulin-resistance causes. [16][21][23]", "Treat the driver first: weight reduction, discontinuation of a causative medication, treatment of an endocrinopathy, or cancer-directed therapy may improve lesions; lesion-directed treatment is principally cosmetic. [21]" ], "sections": [ { "id": "etiologic-triage", "eyebrow": "First decision", "heading": "Classify the presentation before ordering tests", "intro": "The distribution, tempo, body habitus, and extracutaneous findings determine the initial workup.", "paragraphs": [ "Confirm the clinical phenotype: symmetric, hyperpigmented, velvety plaques with poorly defined borders, usually in intertriginous areas, support acanthosis nigricans. Skin tags commonly coexist around affected sites in insulin-resistant phenotypes. [21][23]", "The common branch is obesity-associated insulin resistance. In children, adolescents, and adults with overweight or central adiposity, neck and axillary involvement should redirect the encounter toward dysglycemia, dyslipidemia, hypertension, and fatty-liver risk rather than biopsy or lesion-directed therapy. Acanthosis nigricans identifies higher metabolic risk, but obesity is more predictive of insulin resistance than the skin finding alone. [2][22][24]", "Escalate beyond routine metabolic assessment when lesions are abrupt, rapidly progressive, extensive or generalized, involve oral or other mucosa, or arise in a nonobese patient without an evident insulin-resistant state. Malignant lesions can be clinically indistinguishable from benign lesions; gastrointestinal adenocarcinoma, particularly gastric carcinoma, is the classic association. [16][21][23]" ], "bullets": [ "Ask about tempo: longstanding lesions tracking with weight gain favor obesity-associated disease; rapid new progression increases concern for a systemic driver. [16][21]", "Review medications and supplements because acanthosis nigricans is associated with drugs as well as insulin resistance, endocrine disorders, chromosomal abnormalities, and neoplasia. [7][21]", "Ask about menstrual irregularity, hirsutism, acne, or virilization; acanthosis nigricans can be a cutaneous marker of polycystic ovary syndrome and other hyperandrogenic states. [6][16][24]", "Ask about symptomatic hypo- or hyperglycemia and autoimmune disease when severe insulin resistance is disproportionate to adiposity; type B insulin resistance may present with either hyperglycemia or hypoglycemia. [9][11]" ], "subsections": [], "table": { "caption": "Clinical patterns that change the next diagnostic step. [6][11][16][21][24]", "columns": [ "Pattern", "Most likely etiologic branch", "Next action" ], "rows": [ [ "Gradual neck/axillary plaques with obesity or central adiposity", "Obesity-associated insulin resistance", "Measure BMI and blood pressure; obtain fasting glucose, hemoglobin A1c, fasting lipid profile, and ALT. [19][24]" ], [ "Acanthosis nigricans with irregular menses, hirsutism, acne, or virilization", "PCOS or another hyperandrogenic insulin-resistant state", "Evaluate the hyperandrogenic syndrome and metabolic comorbidity burden. [6][16][24]" ], [ "Severe generalized disease with marked hyperinsulinemia, dysglycemia, hypoglycemia, or autoimmune features", "Type B insulin resistance", "Obtain paired glucose and insulin/C-peptide during the glycemic phenotype and pursue insulin-receptor antibody testing through an experienced center. [9][11]" ], [ "Abrupt, extensive, mucosal, or nonobese presentation", "Malignancy-associated acanthosis nigricans", "Perform symptom- and examination-directed evaluation for internal malignancy, with particular attention to gastrointestinal cancer. [16][21][23]" ] ] } }, { "id": "metabolic-workup", "eyebrow": "Common pathway", "heading": "Evaluate obesity-associated acanthosis nigricans as a metabolic risk marker", "intro": "The purpose of testing is to identify actionable dysglycemia and cardiometabolic comorbidity.", "paragraphs": [ "At the initial visit, record height, weight, BMI, waist or hip circumference when useful for adiposity assessment, and blood pressure. Examine for skin tags, hirsutism, goiter, abdominal tenderness or hepatomegaly, and broad pink striae when the history suggests endocrine disease. [19][24]", "Obtain fasting plasma glucose and hemoglobin A1c to detect dysglycemia, and obtain a fasting lipid profile to identify atherogenic dyslipidemia. Add ALT when obesity-associated metabolic dysfunction or hepatic steatosis is a concern; overweight and obese children with acanthosis nigricans have demonstrated higher fasting glycemia, insulin, HOMA index, triglyceride-related metabolic abnormalities, and aminotransferase levels than peers without lesions. [19][24]", "Do not use acanthosis nigricans as a stand-alone proxy for insulin resistance or type 2 diabetes. In obese children, the presence of lesions is associated with insulin resistance, but obesity itself remains the more important determinant; a normal glucose result does not negate the need to address excess adiposity and longitudinal metabolic risk. [18][22]" ], "bullets": [ "For youth with obesity plus acanthosis nigricans, recognize the lesion as a sign of insulin resistance that strengthens concern for type 2 diabetes risk. [2][6]", "When fasting glucose and hemoglobin A1c do not explain the clinical phenotype but concern for glucose intolerance remains high, consider an oral glucose tolerance test; OGTT has been used to characterize glucose tolerance and insulin resistance in obese children with acanthosis nigricans. [18][19]", "In patients with obesity-associated disease, use the laboratory results to manage dysglycemia, hypertension, dyslipidemia, and suspected fatty liver rather than treating pigment alone. [19][24]" ], "subsections": [], "table": null }, { "id": "uncommon-causes", "eyebrow": "Escalation", "heading": "Recognize endocrine, autoimmune, and malignancy-associated patterns", "intro": "Rare causes matter when phenotype severity or clinical context is discordant with ordinary obesity-associated disease.", "paragraphs": [ "Consider endocrine-associated acanthosis nigricans when there are syndrome-specific findings. Hyperandrogenic and hypogonadal states, Cushing disease, Addison disease, hypothyroidism, and diabetes-related insulin resistance have been reported associations. In a patient with corresponding symptoms or examination findings, test for the suspected disorder rather than applying a broad endocrine panel. [10][16]", "Type B insulin resistance is an autoimmune syndrome caused by insulin-receptor autoantibodies and can produce severe insulin resistance with hyperglycemia or, less often, hypoglycemia. During a spontaneous hypoglycemic event, obtain glucose with insulin, proinsulin, and C-peptide; confirmation requires insulin-receptor autoantibody detection. The coexistence of acanthosis nigricans, extreme hyperinsulinemic biochemistry, autoimmune features, and hyperandrogenism or female virilization should prompt urgent endocrinology involvement. [9][11]", "For suspected malignant acanthosis nigricans, use history and examination to direct cancer testing rather than assuming that lesion morphology distinguishes malignant from metabolic disease. Gastric carcinoma is the most common reported tumor association, and adenocarcinomas of the gastrointestinal tract, ovary, lung, and breast have been described. Mucosal involvement may include the oral cavity, nasal or laryngeal mucosa, or esophagus. [16][23]" ], "bullets": [ "A nonobese patient with new acanthosis nigricans and no evident insulin-resistant phenotype needs malignancy assessment and medication review. [16][21]", "Mucosal lesions or widespread papillomatous disease increase the need to investigate a paraneoplastic pattern, while recognizing that mucosal lesions have also been reported in acanthosis nigricans generally. [16][23]", "Do not infer that correction of hypothyroidism alone will resolve acanthosis nigricans or hyperinsulinemia; reported cases showed persistence after thyroid correction. [10]" ], "subsections": [], "table": null }, { "id": "management", "eyebrow": "Treatment", "heading": "Treat the underlying driver before cosmetic therapy", "intro": "Improvement in plaques follows reduction of the pathogenic stimulus more reliably than lesion-only treatment.", "paragraphs": [ "For obesity-associated acanthosis nigricans, make weight reduction and treatment of insulin resistance the primary intervention. Weight loss can improve obesity-related disease, and control of hyperinsulinemia through dietary change may reduce lesion severity. Treat documented diabetes, dyslipidemia, hypertension, polycystic ovary syndrome, or suspected fatty-liver disease according to the relevant disease pathway. [14][16][21]", "When an identifiable medication is implicated, discontinue or substitute it when clinically feasible. If a defined endocrinopathy or internal malignancy is driving the lesions, direct treatment to that disorder; this approach may improve acanthosis nigricans and avoids ineffective escalation of cosmetic therapies. [21]", "Use lesion-directed therapy only after addressing the driver and clarifying that evidence is largely symptomatic or cosmetic. Localized lesions may be treated with topical retinoids, vitamin D analogs, chemical peels, or other keratolytics; systemic oral retinoids have been considered for extensive, generalized, or topical-treatment–unresponsive disease. Laser therapy, dermabrasion, and surgical removal are less common options. [21]" ], "bullets": [ "Metformin has been reported to improve insulin resistance and acanthosis nigricans after treatment for at least 6 months, but the reviewed material does not establish a lesion-specific dose or make it a substitute for indication-based metabolic treatment. [15][22]", "Tazarotene has been reported as symptomatic treatment in juvenile familial obesity-associated acanthosis nigricans; select topical therapy for cosmetic goals, not to exclude or treat systemic disease. [4]", "Reassess lesion trajectory alongside body weight and the identified metabolic or systemic driver; continued rapid progression should reopen evaluation for an alternative cause. [16][21]" ], "subsections": [], "table": { "caption": "Management priorities by etiologic branch. [14][15][16][21][22]", "columns": [ "Etiology", "Primary intervention", "Role of skin-directed therapy" ], "rows": [ [ "Obesity-associated insulin resistance", "Weight reduction and treatment of documented metabolic comorbidities. [14][16][21]", "Consider topical retinoids, vitamin D analogs, peels, or keratolytics for residual cosmetic concern. [21]" ], [ "Medication-associated disease", "Discontinue or replace the causative medication when feasible. [21]", "Use only if lesions remain bothersome after medication review. [21]" ], [ "Endocrinopathy or PCOS-associated disease", "Treat the identified endocrine or hyperandrogenic disorder and associated insulin resistance. [16][21][24]", "Adjunctive only. [21]" ], [ "Malignancy-associated disease", "Treat the underlying malignancy after directed diagnostic evaluation. [21]", "Do not allow cosmetic treatment to delay cancer evaluation. [21]" ], [ "Type B insulin resistance", "Confirm insulin-receptor autoantibodies and manage with specialized endocrinology input. [11]", "No primary role until the systemic disorder is addressed. [21]" ] ] } }, { "id": "biopsy-and-referral", "eyebrow": "Diagnostic limits", "heading": "Use biopsy selectively and refer for discordant disease", "intro": "Histology may support the diagnosis but does not replace etiologic assessment.", "paragraphs": [ "Clinical diagnosis is usually sufficient when the morphology and metabolic context are typical. Consider dermatology evaluation and biopsy when morphology is atypical, distribution is unusual, facial pigmentation raises competing diagnoses, or a mimicker such as an acanthosis nigricans-like variant of mycosis fungoides is plausible. Patch-stage mycosis fungoides may require multiple skin biopsies. [13][17]", "Refer urgently to endocrinology for suspected type B insulin resistance or severe dysglycemia with disproportionate hyperinsulinemia, and coordinate expedited malignancy evaluation for rapid, generalized, mucosal, or nonobese disease. The referral question should specify the phenotype, lesion tempo, glucose pattern, insulin/C-peptide results when obtained, medication exposures, and systemic cancer symptoms. [9][11][16][21]" ], "bullets": [ "Biopsy does not distinguish benign from malignant acanthosis nigricans reliably because malignant lesions may be clinically indistinguishable from benign lesions. [23]", "For facial hyperpigmentation, reconsider facial acanthosis nigricans and competing pigmentary disorders before initiating depigmenting or keratolytic treatment. [17]" ], "subsections": [], "table": null } ], "faq": [], "references": [ { "number": 1, "title": "[PDF] 210874Orig1s000 CLINICAL REVIEW(S) - accessdata.fda.gov", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210874Orig1s000MedR.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov" }, { "number": 2, "title": "Type 2 diabetes in children - Symptoms, diagnosis and treatment | BMJ Best Practice US", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-us/786", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com" }, { "number": 3, "title": "Cutaneous Manifestations of Internal Malignancy", "detail": "acsjournals.onlinelibrary.wiley.com", "url": "https://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.3322/caac.20005", "authors": "acsjournals.onlinelibrary.wiley.com", "host": "acsjournals.onlinelibrary.wiley.com" }, { "number": 4, "title": "Acanthosis nigricans: A review - Journal of Cosmetic Dermatology", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1111/jocd.13544", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 5, "title": "Cutaneous Manifestations of Internal Malignancy - Thiers - 2009 - CA", "detail": "acsjournals.onlinelibrary.wiley.com", "url": "https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.20005", "authors": "acsjournals.onlinelibrary.wiley.com", "host": "acsjournals.onlinelibrary.wiley.com" }, { "number": 6, "title": "ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/pedi.13409", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 7, "title": "Posters - 2017 - Australasian Journal of Dermatology", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1111/ajd.21_12652", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 8, "title": "Global hotspots and trends in Acanthosis nigricans research: A ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/srt.70054", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 9, "title": "A case of type B insulin resistance presenting at a district general ...", "detail": "wchh.onlinelibrary.wiley.com", "url": "https://wchh.onlinelibrary.wiley.com/doi/10.1002/pdi.2275", "authors": "wchh.onlinelibrary.wiley.com", "host": "wchh.onlinelibrary.wiley.com" }, { "number": 10, "title": "Acanthosis nigricans, hypothyroidism, and insulin resistance - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/0002934386901828", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 11, "title": "Autoimmune Forms of Hypoglycemia : Medicine", "detail": "journals.lww.com", "url": "https://journals.lww.com/md-journal/fulltext/2009/05000/autoimmune_forms_of_hypoglycemia.2.aspx", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 12, "title": "Acanthosis Nigricans Identifies Youth at High Risk for Metabolic Abnormalities - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0022347609006441", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 13, "title": "Mycosis fungoides: a review - Oxford Academic", "detail": "academic.oup.com", "url": "https://academic.oup.com/ced/advance-article-pdf/doi/10.1093/ced/llaf341/63867538/llaf341.pdf", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 14, "title": "Successful treatment of acanthosis nigricans with etretinate - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0190962209802429", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 15, "title": "An approach to acanthosis nigricans : Indian Dermatology Online Journal", "detail": "journals.lww.com", "url": "https://journals.lww.com/idoj/fulltext/2014/05030/an_approach_to_acanthosis_nigricans.1.aspx", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 16, "title": "Acanthosis Nigricans - an overview | ScienceDirect Topics", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/acanthosis-nigricans", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 17, "title": "Facial acanthosis nigricans − a narrative review : Pigment International", "detail": "journals.lww.com", "url": "https://journals.lww.com/pigi/fulltext/2023/10020/facial_acanthosis_nigricans___a_narrative_review.2.aspx", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 18, "title": "Acanthosis nigricans is a reliable cutaneous marker of insulin resistance in obese Japanese children - PubMed", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pubmed/14651545", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 19, "title": "[PDF] PHC ENG GUIDE 200 - Extranet Systems", "detail": "extranet.who.int", "url": "https://extranet.who.int/ncdccs/Data/LBN_D1_Final%20EN%20PHC%20Guide%20(September%2025,%202015).pdf", "authors": "extranet.who.int", "host": "extranet.who.int" }, { "number": 20, "title": "Predictors of Insulin Treatment During Pregnancy and Abnormal Postpartum Glucose Metabolism in Patients with Gestational Diabetes Mellitus - PubMed", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pubmed/31853192", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 21, "title": "Acanthosis Nigricans: An Updated Review - PubMed", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pubmed/36698243", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 22, "title": "An approach to acanthosis nigricans - PMC", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144206", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 23, "title": "A STUDY OF PATHOGENESIS OF ACANTHOSIS NIGRICANS AND ITS CLINICAL IMPLICATIONS", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3276896", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 24, "title": "Acanthosis Nigricans – A Two-Sided Coin: Consider Metabolic Syndrome and Malignancies! - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6910804", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "[PDF] 210874Orig1s000 CLINICAL REVIEW(S) - accessdata.fda.gov", "detail": "www.accessdata.fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210874Orig1s000MedR.pdf", "authors": "www.accessdata.fda.gov", "host": "www.accessdata.fda.gov", "snippet": "& Premalignant Conditions MedDRA PTs: 5q minus syndrome; 5q minus syndrome; Abdominal neoplasm; Abdominal wall neoplasm; Abdominal wall neoplasm malignant; Acanthosis nigricans; Acinar cell carcinoma of pancreas; Acinic cell carcinoma of salivary gland; Acquired thalassaemia; Acral lentiginous melan", "score": 0.468621 }, { "number": 2, "title": "Type 2 diabetes in children - Symptoms, diagnosis and treatment | BMJ Best Practice US", "detail": "bestpractice.bmj.com", "url": "https://bestpractice.bmj.com/topics/en-us/786", "authors": "bestpractice.bmj.com", "host": "bestpractice.bmj.com", "snippet": "Often asymptomatic and diagnosed by screening in a high-risk individual (e.g., family history, obesity, acanthosis nigricans) or incidentally (e.g., glycosuria found during a school or sports exam).\n\nThe development of insulin resistance and glucose intolerance can be prevented or delayed by lifesty", "score": 0.32527456 }, { "number": 3, "title": "Cutaneous Manifestations of Internal Malignancy", "detail": "acsjournals.onlinelibrary.wiley.com", "url": "https://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.3322/caac.20005", "authors": "acsjournals.onlinelibrary.wiley.com", "host": "acsjournals.onlinelibrary.wiley.com", "snippet": "Acanthosis nigricans commonly occurs in obese per- sons, especially dark-skinned teenagers, in associa- tion with insulin resistance and other endocrinopa-", "score": 0.58976424 }, { "number": 4, "title": "Acanthosis nigricans: A review - Journal of Cosmetic Dermatology", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1111/jocd.13544", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "Successful symptomatic tazarotene treatment of juvenile acanthosis nigricans of the familial obesity-associated type in insulin resistance.", "score": 0.572078 }, { "number": 5, "title": "Cutaneous Manifestations of Internal Malignancy - Thiers - 2009 - CA", "detail": "acsjournals.onlinelibrary.wiley.com", "url": "https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.20005", "authors": "acsjournals.onlinelibrary.wiley.com", "host": "acsjournals.onlinelibrary.wiley.com", "snippet": "Acanthosis nigricans commonly occurs in obese persons, especially dark-skinned teenagers, in association with insulin resistance and other", "score": 0.5663309 }, { "number": 6, "title": "ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/pedi.13409", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "Signs of insulin resistance (acanthosis nigricans, HTN, dyslipidemia, polycystic ovary syndrome), low birth weight (small for gestational age)", "score": 0.5391051 }, { "number": 7, "title": "Posters - 2017 - Australasian Journal of Dermatology", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1111/ajd.21_12652", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "Acanthosis nigricans is a dermatopathy associated with insulin-resistance, drugs, endocrine disorders, chromosome abnormalities and neoplasia,", "score": 0.529337 }, { "number": 8, "title": "Global hotspots and trends in Acanthosis nigricans research: A ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/srt.70054", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "Acanthosis nigricans (AN) is a common skin disease. AN is associated with obesity, insulin resistance, the most common dermatological condition", "score": 0.51413256 }, { "number": 9, "title": "A case of type B insulin resistance presenting at a district general ...", "detail": "wchh.onlinelibrary.wiley.com", "url": "https://wchh.onlinelibrary.wiley.com/doi/10.1002/pdi.2275", "authors": "wchh.onlinelibrary.wiley.com", "host": "wchh.onlinelibrary.wiley.com", "snippet": "Acanthosis nigricans is often described. Less common presenting features include hypoglycaemia and hyperandrogenism/female virilisation. There", "score": 0.32190803 }, { "number": 10, "title": "Acanthosis nigricans, hypothyroidism, and insulin resistance - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/0002934386901828", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "## The American Journal of Medicine. # Acanthosis nigricans, hypothyroidism, and insulin resistance. Acanthosis nigricans has been associated with multiple endocrinopathies. Three patients are described (one woman and two men) who presented with hypothyroidism and acanthosis nigricans. All the patie", "score": 0.643173 }, { "number": 11, "title": "Autoimmune Forms of Hypoglycemia : Medicine", "detail": "journals.lww.com", "url": "https://journals.lww.com/md-journal/fulltext/2009/05000/autoimmune_forms_of_hypoglycemia.2.aspx", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Title: Autoimmune Forms of Hypoglycemia : Medicine\nAutoimmune syndromes are a rare cause of hypoglycemia characterized by elevated levels of insulin in the presence of either anti-insulin antibodies (insulin autoimmune syndrome) or anti-insulin receptor antibodies (type B insulin resistance). Also, ", "score": 0.5689194 }, { "number": 12, "title": "Acanthosis Nigricans Identifies Youth at High Risk for Metabolic Abnormalities - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0022347609006441", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "### J Clin Endocrinol Metab\n\n### Prevalence of impaired glucose tolerance among children and adolescents with marked obesity\n\n### N Engl J Med\n\n### Acanthosis Nigricans, insulin resistance (HOMA) and dyslipidemia among Native American children\n\n### J Okla State Med Assoc\n\n### Acanthosis nigricans: a", "score": 0.41819844 }, { "number": 13, "title": "Mycosis fungoides: a review - Oxford Academic", "detail": "academic.oup.com", "url": "https://academic.oup.com/ced/advance-article-pdf/doi/10.1093/ced/llaf341/63867538/llaf341.pdf", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "Patients may require multiple skin biopsies, especially at the patch stage, rare subtypes include: Acanthosis nigricans-like", "score": 0.2662051 }, { "number": 14, "title": "Successful treatment of acanthosis nigricans with etretinate - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0190962209802429", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Title: Successful treatment of acanthosis nigricans with etretinate - ScienceDirect\n## Article preview. ## First page preview. Click to open first page preview. ### Acanthosis nigricans: a cutaneous marker of tissue resistance to insulin. ### Acanthosis nigricans and endocrine disease. ### Classific", "score": 0.5962692 }, { "number": 15, "title": "An approach to acanthosis nigricans : Indian Dermatology Online Journal", "detail": "journals.lww.com", "url": "https://journals.lww.com/idoj/fulltext/2014/05030/an_approach_to_acanthosis_nigricans.1.aspx", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Title: An approach to acanthosis nigricans : Indian Dermatology Online Journal\n## ACANTHOSIS NIGRICANS AND INSULIN RESISTANCE. Acanthosis nigricans patients have hyperinsulinemia and may be at greater risk of atherosclerotic cardiovascular disease.[19] The commonest underlying cause of IR is excess ", "score": 0.5360463 }, { "number": 16, "title": "Acanthosis Nigricans - an overview | ScienceDirect Topics", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/acanthosis-nigricans", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Title: Acanthosis Nigricans - an overview | ScienceDirect Topics\nAcanthosis nigricans is most often associated with insulin resistance. A malignant form of acanthosis nigricans is rare: these patients are not obese and often have a glossitis (see Chapter 13). Some patients have a malignant type of a", "score": 0.49157855 }, { "number": 17, "title": "Facial acanthosis nigricans − a narrative review : Pigment International", "detail": "journals.lww.com", "url": "https://journals.lww.com/pigi/fulltext/2023/10020/facial_acanthosis_nigricans___a_narrative_review.2.aspx", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Title: Facial acanthosis nigricans − a narrative review : Pigment International\n# Facial acanthosis nigricans − a narrative review. **Background:** Facial acanthosis nigricans (AN) is usually a misdiagnosed facial melanosis, most commonly seen in obese individuals. **Aims:** This review aims to focu", "score": 0.43669468 }, { "number": 18, "title": "Acanthosis nigricans is a reliable cutaneous marker of insulin resistance in obese Japanese children - PubMed", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pubmed/14651545", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "Title: Acanthosis nigricans is a reliable cutaneous marker of insulin resistance in obese Japanese children - PubMed\nAn official website of the United States government. Federal government websites often end in .gov or .mil. official website and that any information you provide is encrypted. ## Save", "score": 0.5852203 }, { "number": 19, "title": "[PDF] PHC ENG GUIDE 200 - Extranet Systems", "detail": "extranet.who.int", "url": "https://extranet.who.int/ncdccs/Data/LBN_D1_Final%20EN%20PHC%20Guide%20(September%2025,%202015).pdf", "authors": "extranet.who.int", "host": "extranet.who.int", "snippet": "3. Fundoscopic examination.\n4. Palpation of the thyroid.\n5. Examination of the skin (for acanthosis nigricans).\n6. Comprehensive foot examination.\na. Inspect the skin for integrity especially between toes and under metatarsal heads. Look for areas of erythema, warmth or callus formation. Check for b", "score": 0.45391592 }, { "number": 20, "title": "Predictors of Insulin Treatment During Pregnancy and Abnormal Postpartum Glucose Metabolism in Patients with Gestational Diabetes Mellitus - PubMed", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pubmed/31853192", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "Title: Predictors of Insulin Treatment During Pregnancy and Abnormal Postpartum Glucose Metabolism in Patients with Gestational Diabetes Mellitus - PubMed\nAn official website of the United States government. The **https://** ensures that you are connecting to the. official website and that any infor", "score": 0.35716435 }, { "number": 21, "title": "Acanthosis Nigricans: An Updated Review - PubMed", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pubmed/36698243", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "nigricans and for those whose underlying cause is not amenable to treatment, treatment of the lesion may be considered for cosmetic reasons. Topical retinoids, vitamin D analogs, chemical peels, and other keratolytics are often used for the treatment of localized lesions. Seldom, systemic therapy su", "score": 0.54187006 }, { "number": 22, "title": "An approach to acanthosis nigricans - PMC", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144206", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "**Keywords:** Acanthosis nigricans, insulin resistance, obesity. Patients with AN, especially childhood benign AN, are at risk for obesity, hypertension, hyperinsulinemia, IR and type 2 diabetes and AN may be used as reliable index of IR.[14] But obesity is a more important determinant of IR than AN", "score": 0.49875546 }, { "number": 23, "title": "A STUDY OF PATHOGENESIS OF ACANTHOSIS NIGRICANS AND ITS CLINICAL IMPLICATIONS", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3276896", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "## is a dermatosis characterized by velvety, papillomatous, brownish-black, hyperkeratotic plaques, typically on the intertriginous surfaces and neck. Although AN is associated with malignancy, the recognition of its more common connection to obesity and insulin resistance allows for diagnosis of r", "score": 0.80442166 }, { "number": 24, "title": "Acanthosis Nigricans – A Two-Sided Coin: Consider Metabolic Syndrome and Malignancies! - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6910804", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "Overweight and obese children with AN demonstrate significantly higher levels for uric acid, fasting glycemia, insulin, glutamic oxalacetic transaminase, and homeostasis model assessment index than those without AN . This suggests that AN is a marker of increased risk for metabolic syndrome in child", "score": 0.69697046 } ], "publishedAt": "2026-09-15T23:10:20.981266+00:00", "updatedAt": "2026-09-15T23:10:20.981266+00:00", "readingMinutes": 6, "slug": "acanthosis-nigricans" }